Amivantamab
Amivantamab
not stated in source · Single arm
ACC (n = 21)
responders: 1 patients (of 21), results posted 05.08.2026
median progression-free survival: 4.6 months, results posted 05.08.2026
Amivantamab in ACC · NCT05074940
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
ACC pipeline
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
18 arms have a reported figure.
Amivantamab
not stated in source · Single arm
ACC (n = 21)
responders: 1 patients (of 21), results posted 05.08.2026
median progression-free survival: 4.6 months, results posted 05.08.2026
Amivantamab in ACC · NCT05074940
Axitinib 5 mg twice daily
5 mg · ITT
R/M ACC with progression within 9 months (n = 60 total)
Comparator: observation
median progression-free survival: 10.8 months, primary analysis
6-month progression-free survival: 73%, 6 months
progression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guideline
objective response rate: 0%, primary analysis
disease control rate: 100%, primary analysis
Axitinib vs observation (randomized Phase 2) · NCT02859012
Observation
none · ITT
R/M ACC with progression within 9 months
median progression-free survival: 2.8 months, primary analysis
6-month progression-free survival: 23%, 6 months
disease control rate: 51.9%, primary analysis
median overall survival: 27.2 months, axitinib median not reached; P 0.226
Axitinib vs observation (randomized Phase 2) · NCT02859012
Axitinib + avelumab
axitinib 5 mg twice daily + avelumab · Single arm
R/M ACC (n = 28 evaluable)
confirmed objective response rate: 18%, primary analysis
median progression-free survival: 7.3 months, primary analysis
median overall survival: 16.6 months, primary analysis
Axitinib + avelumab, ACC-I subtype
as above · Single arm
ACC-I (exploratory biomarker analysis of 28 patients)
median progression-free survival: 1.8 months, updated analysis; exploratory
Axitinib + avelumab, ACC-II subtype
as above · Single arm
ACC-II (exploratory)
median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I
Emi-Le, ACC efficacy cohort
Phase 1 doses (not stated in source) · Single arm
R/M ACC, evaluable (n = 45)
objective response rate: 35.6%, ASCO 2026
disease control rate: 82.2%, ASCO 2026
median duration of response: 7.4 months, ASCO 2026
Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) · NCT05377996
Emi-Le, post hoc aggressive subtype
Phase 1 doses (not stated in source) · Single arm
ACC with solid histology or high-grade transformation (n = 32, post hoc)
objective response rate: 46.9%, ASCO 2026; post hoc
median progression-free survival: 7.8 months, ASCO 2026; post hoc
median duration of response: 6.4 months, ASCO 2026; post hoc
Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) · NCT05377996
Lenvatinib 24 mg
24 mg · Single arm
progressive R/M ACC (n = 32 evaluable)
objective response rate: 15.6%, primary analysis
median progression-free survival: 17.5 months, 8 progression events
Lenvatinib MSK Phase 2 · NCT02780310
Lenvatinib 24 mg
24 mg · Single arm
R/M salivary ACC (n = 26 evaluable)
objective response rate: 11.5%, primary analysis
median progression-free survival: 9.1 months, primary analysis
median overall survival: 27 months, primary analysis
ACC-LEN14 · NCT02860936
Lenvatinib + pembrolizumab
not stated in source · Single arm
progressive R/M ACC (n = 17 evaluable)
objective response rate: 6%, ASCO 2023 (search record)
Lenvatinib + pembrolizumab · NCT04209660
AL101 4 mg
4 mg · Single arm
R/M ACC with NOTCH1 to 4 activating mutation (n = 45)
responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024
median overall survival: 9.3 months, final
ACCURACY · NCT03691207
AL101 6 mg
6 mg · Single arm
R/M ACC with NOTCH activating mutation (n = 42)
responders (CR or PR): 2 patients (of 42), final
median overall survival: 9.4 months, final
ACCURACY · NCT03691207
Regorafenib
not stated in source · Single arm
progressive R/M ACC (n = 38)
responders (CR or PR): 1 patients (of 38), results posted 09.10.2025
Regorafenib in ACC · NCT02098538
REM-422 24 mg (RP2D), biomarker positive
24 mg · Single arm
R/M ACC, MYB biomarker positive at RP2D (n = 7)
objective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)
disease control rate: 100%, ASCO 2026
ARIA · NCT06118086
REM-422 12 mg or more, biomarker positive
12 to 48 mg · Single arm
biomarker-positive R/M ACC (n = 30)
any target-lesion reduction: 70%, cutoff 01.07.2026
target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026
ARIA · NCT06118086
RGT-61159 at or below RP2D
at or below RP2D (mixed doses) · Single arm
R/R ACC, evaluable (n = 39)
disease control rate: 84.6%, ASCO 2026, preliminary
partial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending
RGT-61159 Phase 1a/b · NCT06462183
Rivoceranib 700 mg
700 mg · Single arm
R/M ACC (n = 80; 72 evaluable)
objective response rate (investigator): 15.3%, primary analysis
objective response rate (independent review): 9.7%, primary analysis
median progression-free survival: 9 months, primary analysis
median duration of response (investigator): 14.9 months, primary analysis
Rivoceranib Phase 2 · NCT04119453
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.